The company was incorporated as a public company, limited by shares, under the Companies Act, 1956, as amended, in the name of ‘Akums Drugs and Pharmaceuticals Limited’, pursuant to a certificate of incorporation dated April 19, 2004 issued by the Registrar of Companies, Delhi and Haryana in New Delhi (RoC). The company received a certificate of commencement of business issued by the RoC dated May 13, 2004. 

Established in 2004,  Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. As one of the leading CDMOs in India, the company owns the intellectual property for the manufacturing processes of several of its formulations, and its core business is focused on providing end-to-end product development and manufacturing solutions to its clients. Some of its other services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and global markets, and other testing services. In addition to its core CDMO business, it is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs).

Business area of the company 

As a CDMO, the company produces an extensive range of dosage forms including tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies, among others. It also engages in the marketing of trade generic and products under its own brand through distributors and alternative channels across India.  

Key Awards and accreditations

• 2018: Received India Pharma Leader Award by Government of India.
• 2019: Received India Pharma Leader Award by Government of India.
• 2021: Award for India Pharma Award for Excellence in Contract Research and Manufacturing by Informamarkets. 
• 2022: Award for Excellence in R&D and Innovation by ET Ascent.
• 2022: Awarded the International Healthcare award as Pharmaceutical Company of the Year in contract manufacturing by Times Cyber Media.
• 2022: Awarded the Excellence in Operations – Manufacturing by CPHI Awards.
• 2022: Awarded Asia’s Pharma Excellence Awards in Innovation in Nutraceutical, Cosmetic and Wellness Award by CMO Asia.
• 2023: Awarded Dream Employer of the Year by Times Ascent.
• 2023: Awarded the Excellence Award in Nutraceutical category by IHW Council.
• 2023: Award for the best brand based in North India by Exchange4Media. 
• 2023: Awarded the best Technology Adaption – Cash Management Services by HDFC Bank.
• 2023: Awarded 2nd Runner up in Best Trademarks portfolio by CII Industrial Intellectual Property Awards. 
• 2023: Awarded the Excellence in Formulations by India Pharma World Awards, The Economic Times. 
• 2023: Awarded the Most Admired Quality Pharmaceutical Manufacturer of India 2023 by Observe Now. 
• 2023: Awarded the Certificate of Appreciation for Excellence in Innovative Formulations – Nutraceutical and Wellness Award by Food Safety and Nutrition Summit and Awards 2023.

Major events and milestones

• 2004: Incorporation of the company.
• 2004: Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand. 
• 2007: Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand.
• 2009: Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals.
• 2010: Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand.
• 2010: Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand.
• 2010: Incorporated Akumentis Healthcare Limited to venture into branded formulations.
• 2011: Innovated bi-layered sustained release tablets for the first time.
• 2012: Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities.
• 2013: Innovated tablet-in-tablet sustained release tablets for the first time.
• 2013: Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities.
• 2013: Expanded into the African market.
• 2015: Expanded into the Asian market.
• 2015: Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market.
• 2016: Maxcure Nutravedics Limited received US-NSF certification.
• 2019: Investment by Ruby QC Investment Holdings Pte. Ltd. in the company to become a minority shareholder.
• 2021: Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs.
• 2021: Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited.
• 2022: Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets.
• 2022: Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited.
• 2023: Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited.
• 2023: Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited.